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Summary Ten human ovarian carcinoma cell lines have been studied as a potential in vitro screen for the
development of novel anticancer platinum complexes. Lines have been established and developed both from
solid and ascitic tumours, from pretreated and untreated patients, and are available at a range of in vitro
passage numbers. The biological properties of the lines were consistent with them being human, epithelial and
of ovarian carcinoma origin. Using a tritiated thymidine or leucine uptake method, and a 96 hour continuous
drug exposure, the lines have been calibrated against four platinum-containing chemotherapeutic agents:
cisplatin, iproplatin, carboplatin and tetraplatin. Striking differences in cytotoxicity were observed across the
lines for each agent. Some lines were consistently resistant, others generally sensitive, whereas some showed
clear evidence of differential sensitivity to a particular agent. Statistical analysis (Spearman rank correlation)
involving the six possible pairings of drugs showed that cisplatin, iproplatin and carboplatin elicit a very
similar pattern of response in these lines whereas tetraplatin elicits a completely different response pattern.
Similar cytotoxicity values were obtained using a soft agar cloning assay. Results using a tetrazolium dye
reduction assay, however, gave somewhat higher and more variable values, particularly with tetraplatin. The
thymidine uptake assay will be adopted in further studies on a selected panel of six lines. This panel
encompasses the spectra of sensitivities identified for each of the four agents against the original ten lines and
may provide a useful screening facility for the development of novel platinum drugs, in that it detects both
cell line-determined and structure-determined differences in cytotoxicity.
Traditionally, the development of new drugs for the treat-
ment of malignant diseases has relied predominantly on
transplantable murine tumour models, such as those used by
the National Cancer Institute (NCI) (Frei, 1982; Venditti,
1983). Such models include the P388 leukaemia, L1210
leukaemia, Lewis lung carcinoma, B16 melanoma, Colon 38
and CD8F1 mammary carcinoma. Our earlier work, which
predicted the clinical antitumour activities of the platinum
analogues JM8 (carboplatin) and JM9 (iproplatin), exploited
predominantly the platinum-sensitive ADJ/PC6 murine
plasmacytoma (Harrap et al., 1980; Harrap, 1985). Other
workers have generated cisplatin-resistant variants of the
L1210 and P388 tumours in attempts to identify novel
platinum drugs which might exhibit wider spectra of anti-
tumour activities (Burchenal et al., 1979, 1980). Tetraplatin
exhibits no cross-resistance in such models and is currently
under preclinical development at NCI (Anderson et al.,
1986). A recent reappraisal of screening models at the NCI
has resulted in the replacement of the in vivo murine panel in
favour of a range of in vitro human tumour cell lines
representative of the major histological types (Boyd, 1986).
Clinical trials using platinum-containing chemotherapeutic
agents (mainly cisplatin and carboplatin) have thus far
demonstrated good antitumour activity in testicular semi-
noma and teratoma (Wiltshaw & Carr, 1974; Peckham et al.,
1985), in ovarian carcinoma (with response rates typically
around 50%) (Wiltshaw & Carr, 1974; Wiltshaw, 1985;
Calvert et al., 1985) and lesser activity in other tumour types
such as small cell lung cancer and carcinoma of the cervix.
Future objectives in platinum drug development must
embrace the discovery of agents which, in addition to
possessing favourable normal cell toxicity profiles and simi-
lar antitumour activity to cisplatin, also show activity in
disease currently resistant to cisplatin.
A panel of ovarian carcinoma cell lines representative of
the spectrum of patient response to existing chemotherapy
may be of relevance as an in vitro screen for new platinum-
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containing agents. There have been a number of recent
reports describing the establishment of ovarian carcinoma
cell lines (Woods et al., 1979; Simon et al., 1983; Van
Haaften-Day et al., 1983; Buick et al., 1985; Wolf et al.,
1987). This study describes the development and biological
properties of 10 human ovarian carcinoma cell lines. These
have been obtained from both patient ascites and primary
neoplasms, from patients having received chemotherapy
before biopsy or no pretreatment. Six of the lines have also
been established as xenograft lines in nude mice. .Their
potential usefulness as a screen for the development of new
platinum-containing chemotherapeutic agents has been
assessed by calibrating the cell lines against four currently
available agents: cisplatin, JM8 (carboplatin), JM9 (CHIP,
iproplatin) and tetraplatin.
Materials and methods
Cell lines
Ten human ovarian carcinoma cell lines have been used in
this study. SKOV-3 (Fogh et al., 1977), OVCAR-3
(Hamilton et al., 1983) and PAl (Zeuthen et al., 1980) were
obtained from the American Type Culture Collection.
OAW42 (Wilson, 1984), OAW28, 41M and 59M were estab-
lished by one the authors (A.P.W.). Details of these lines
(OAW28, 41M and 59M) are in preparation for separate
publication. PXN/94 and HX/62 were established from
human ovarian xenograft lines grown in female nude (Nu/
Nu) mice in this department and CHI was established from
an ascites sample within the department. Details of the
tumour histology, source of biopsy and pre- and post-biopsy
treatments are shown in Table I, which indicates that lines
have been established from both solid and ascitic tumours,
from xenograft lines, and from pretreated (chemotherapy
and radiotherapy) or untreated patients.
All lines grew as monolayer cultures and, with the excep-
tion of 41M, were grown in Dulbecco's Modified Eagle's
Medium (DMEM) supplemented with 10% fetal calf serum
(Imperial Laboratories, Salisbury, UK), 50 igml-1 genta-
micin, 2.5 igml-1 amphotericin B, 2mM glutamine, plus
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Table I Patient information for each cell line
Treatment
Cell Pre-biopsy Post-biopsy
line Histology Source of sample Treatment Response Treatment Response
SKOV-3 Ovarian Ascites Thiotepa n.k. n.k. n.k.
adenocarcinoma
OAW42 Serous Ascites Cisplatin c.r. p.d.
cystadenocarcinoma Died
OVCAR-3 Ovarian Ascites Cyclophosphamide n.k. n.k. n.k.
adenocarcinoma Adriamycin
Cisplatin
41M Ovarian Ascites None Cyclophosphamide p.r.
adenocarcinoma Relapsed
Died
59M Endometrioid Ascites None Ifosfamide p.r.
carcinoma of ovary Melphalan Died
(with clear cell
components)
CHI Papillary Ascites Cisplatin c.r. Mitoxanthrone+ Died
cystadenocarcinoma JM8 p.r. Provera
OAW28 Ovarian Ascites Cisplatin n.r. Died 3 days after
adenocarcinoma Melphalan n.r. sample taken
PXN/94 Ovarian Xenograft tumour JM8 p.r. Cisplatin Toxicity
adenocarcinoma Died
PAl Ovarian Ascites (Chemotherapy) n.r. n.k. Died
teratocarcinoma (n.k.)
HX/62 Papillary Xenograft tumour Radiotherapy+ c.r. Cisplatin+ Pulmonary
cystadenocarcinoma radium Adriamycin+ embolism
Chlorambucil Died
n.k., not known; c.r., complete remission; p.r., partial remission; n.r., no response; p.d., progressive disease.
10jg ml- I insulin and 0.5jgml-1 hydrocortisone as growth
factors in a 10% CO2, 90% air atmosphere. 41M cells were
grown in a 1:1 mixture of DMEM and Hams F12 medium
with the same additives. For the lines established from
xenograft (PXN/94 and HX/62) control of stromal fibroblast
overgrowth was achieved by selective detachment of fibro-
blasts using a 30s incubation with 0.02% EDTA and
through the use of a feeder layer of lethally irradiated Swiss
mouse embryonic fibroblast 3T3 cells as described previously
for other human tumour cells of epithelial origin (Kelland et
al., 1987). Cells were periodically checked and found to be
free of mycoplasma contamination by staining with Hoechst
33528 dye and examining under a fluorescent microscope.
Biological properties
Intermediate filament analysis Detection of intermediate
filament proteins, cytokeratins and vimentin by immuno-
fluorescence was performed using a standard double anti-
body technique on cells fixed on slides with acetone/
methanol. Cytokeratins (nos 8, 18 and 19) were detected
using CAM 5.2 (Makin et al., 1984). Rabbit anti-mouse
immunoglobulin conjugated with fluorescein was used as the
second layer antibody.
Cell surface antigen expression and other markers The onco-
fetal antigens alpha-fetal protein (AFP) and carcino-
embryonic antigen (CEA) were detected immunocyto-
chemically using commercially available monoclonal anti-
bodies (Unipath Oxoid). In addition, markers were used
which recognise cells ofepithelial origin; epithelial membrane
antigen (EMA), and with some specificity toward ovarian
tumours, OC 125 (Bast et al., 1981) obtained from CIS UK
and human milk fat globulin 2, HMFG2
(Taylor-Papadimitriou et al., 1981) obtained from Unipath
Oxoid. Finally we have used a monoclonal antibody
(GCTM-1) donated by Dr Martin Pera of this institute,
which stains the nuclei of all human cells (Pera et al., 1988)
and acts as a positive control for the presence of human
cells.
Cytogenetic analysis Exponentially growing cultures were
treated with 0.2Mgml-1 colcemid for 4 hours. Cells were
then disaggregated using 0.02% EDTA/0.05% trypsin,
centrifuged (lOOg, 5min) and swollen in a hypotonic solu-
tion of 0.075 M KCI for Omin at 37°C. Cells were then fixed
with ice-cold glacial acetic acid:methanol (1:3) and dropped
on to slides. Spreads were air dried and stained with 5%
Giemsa for 10min. Ploidy was also determined using a
fluorescence-activated cell sorter (FACS II). Single cell sus-
pensions were fixed in 70% ethanol, treated with RNase
(100Mg ml-1 for 30min) and propidium iodide (10Mgml-1
for 30min) and fluorescence measured at a wavelength of
488nm.
Population doubling time Growth curves were constructed
by seeding single cells at low density (1 x l0s per T25 flask).
Cells in duplicate flasks were detached at 24-h intervals and
counted using a Coulter counter.
Calibration of cell lines
Four platinum-containing agents were used: cisplatin
(CDDP, neoplatin, cis-diamminedichloroplatinum (II)); ipro-
platin (JM9, CHIP, cis-dichloro-trans-dihydroxy-cis-bis (iso-
propylamine) platinum (IV)); carboplatin (JM8, CBDCA,
paraplatin, cis-diammine-l,1-cyclobutane dicarboxylato-
platinum (II)); and tetraplatin ((trans-d,l) 1,2-diaminocyclo-
hexanetetrachloroplatinum (IV)) (Anderson et al., 1986).
Drugs were obtained from the Johnson Matthey Technology
Centre with the exception of tetraplatin, which was gener-
ously provided by Dr M. Wolpert-Defilippes (NCI,
Bethesda, MD, USA). The chemical structures of these
agents are shown in Figure 1.
Drugs were dissolved at 1 mM in either 0.9% saline or
water (for carboplatin) immediately before use. Assessment
of cytotoxicity was then performed using a labelled thymi-
dine or leucine uptake method as follows. Sub-confluent
flasks of cells were disaggregated using 0.02% EDTA in
0.05% trypsin. Single cell suspensions were then produced by
centrifugation (lOOg, 5min), resuspending in medium and
gently passing through a 19-gauge needle. Viable cells were
then counted using trypan blue dye exclusion and phase
contrast microscopy, and seeded between 5 x 103 and 1 x 104
per well in 96-well plates (Nunc products) in 200,ul of
growth medium. After overnight incubation of cells, drugsDEVELOPMENT OF NOVEL PLATINUM ANTICANCER DRUGS 529
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Figure 1 Structures of the platinum complexes investigated.
were added at various concentrations in triplicate wells for a
total of 96 h. Cytotoxicity was then assessed by adding
either methyl-3H-thymidine 4.2yuCiml-1 (specific activity
5Cimmol-1) for 60min at 37°C or L-4,5-3H-leucine
16.7pyCiml-1 (specific activity 13OCimmol-1) for 120min at
37°C to the cells. Plates were then washed in ice-cold PBS,
held in three separate baths of ice-cold 0.2M perchloric acid
(PCA) for a total of 20min and finally washed three times
with ice-cold methanol. Cells were then solubilised overnight
at 37°C in 100,ul 1N NaOH. The amount of radioactivity
present was determined by neutralising 80pl of sample with
1001 1N HCI, adding 2.4ml Fluoran-HV scintillant (BDH
Chemicals Ltd) and counting in a liquid scintillation counter
(Tricarb 2000 CA, Canberra Packard). Drug doses to inhibit
50% of cell growth (IC50 values) were then determined by
expressing decompositions per minute (d.p.m.) as a percent-
age of control unexposed cells, using a computer software
spreadsheet (Symphony, Lotus Development Corporation).
The IC50 values were then determined by non-linear regres-
sion fitting to a sigmoid curve equation (GraphPad, iSi
Software).
In addition to the labelled thymidine and leucine uptake
assays, cytotoxicity was also assessed using a soft agar cell
cloning assay (Salmon et al., 1978) involving exposure of
cells to drug continuously for 14 days. Further, for means of
comparison, cytotoxicity was determined using an assay
based on the reduction of a soluble tetrazolium dye, XTT
(sodium [(5-phenylaminocarbonyl) tetrazolium-2,3-diyl]-6-
methoxy-4-nitrobenzene-3-sulphonate) (Scudiero et al., 1987),
kindly provided by Dr K. Paull (NCI). As with the thymi-
dine and leucine assays drug exposure was for 96h.
Results
Biological properties
All ten cell lines grew as attached monolayer cultures and
possessed morphological features consistent with cells of
epithelial origin. However, some differences in phase-contrast
morphology were apparent. Some lines such as 41M,
OAW28, PXN/94 and OVCAR-3 grew as small round cells
within tightly adherent colonies, others such as SKOV-3 and
HX/62 consisted of colonies containing much larger poly-
gonal cells, CHI, OAW42, 59M and PA-1 were of inter-
mediate morphology.
Characterisation of the lines with poly and monoclonal
antibody markers is shown in Table II. In addition, the
range in passage number used throughout this study for each
line is shown. Table II shows that all lines were positive
against the GCTM-1 antibody found to be specific for
human cells. In addition, chromosome preparations for each
of the 10 lines confirmed the presence of only human
chromosomes. This reactivity is of particular relevance for
those lines (PXN/94 and HX/62) which were established
from xenograft lines. Intermediate filament analysis showed
the lines to be positive (to varying degrees) for expression of
low molecular weight acidic cytokeratins (found in cells of
epithelial origin). In addition, with the exception of OAW28,
lines showed positivity for vimentin expression.
The OC125 monoclonal antibody recognises the CA125
tumour marker which has been shown to be elevated in
approximately 80% of non-mucinous epithelial ovarian car-
cinomas (Bast et al., 1981, 1983; Buamah et al., 1987). Table
II shows that 9 of the 10 lines (OAW42 being the exception)
possessed elevated levels of this marker. An additional
marker that has been shown to possess some specificity
toward ovarian carcinoma is the HMFG2 antigen with
approximately 94% of epithelial ovarian carcinomas positive
(Ward & Cruickshank, 1987; Ward et al., 1987). Table II
indicates that, as with CA125, 9 of the 10 lines express this
antigen; for HMFG2 the CHI line is the exception.
Of the other marker antigens investigated, the oncofetal
antigens AFP and CEA showed variable expression across
the lines with approximately half positive for each antigen.
Results with CEA are consistent with published studies
which have shown elevated levels in 30-50% of epithelial
ovarian tumours, particularly in poorly differentiated and
advanced disease (Stall & Martin, 1981). All 10 lines were
positive for EMA expression. This is consistent with the
epithelial origin of the lines. All 10 lines were negative for
the expression of oestrogen receptors possessing
<10fmol mg 1 cytosol protein. Under identical assay con-
ditions, two breast carcinoma cell lines MCF7 and ZR75-1
included as positive controls, gave oestrogen receptor
content values of 115 and 306fmolmg-1 cytosol protein
respectively.
Further biological properties of the lines; doubling times
and cytogenetic details are described in Table III. Doubling
Table II_ Characterisation of cell lines with poly and monoclonal marker antibodies
Cell Passage
line no. HMFG2 0CJ25 EMA AFP CEA CAM5.2 Vimentim GCTMI
HX/62 4-6 ++ ++ ++ + + + ++ +
PXN/94 30-40 + + + - + ++ + +
OVCAR-3 16-30 ++ ++ ++ ++ + +
PAl 340-350 + + + - - + + +
OAW42 90-95 + _ ++ _ + + +
59M 10-20 + + ++ ++ + + +
41M 9-11 + + + + + + +
OAW28 15-17 + ++ ++ + + + - +
CHI 12-17 - + ++ + + + + +
SKOV-3 29-45 + + + - - + + +
HMFG2, human milk fat globulin 2 Mab; EMA, epithelial membrane antigen; AFP, alpha-fetoprotein Mab; CEA, carcinoembryonic
antigen Mab; GCTMI, marker for cells of human origin (Pera et al., 1988). Staining intensity: + + highly positive; + positive; -negative.
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Table III Biological properties of the cell lines
Population Cytogenic analysis
Mean Modal
Doubling chromosome chromosome Range
Line time (hr) no. no. no. Ploidya
HX/62 32 82 84 71-92 1.94
PXN/94 23 45 47 38-52 1.25
OVCAR-3 35 66. 65 57-95 1.79
PAl 36 44 44 39-48 1.15
OAW42 19 73 80 52-86 1.88
59M 48 62 52 48-90 1.42
41M 27 43 44 39-49 1.13
OAW28 37 48 44 40-86 1.22
CHI 17 45 46 42-48 1.10
SKOV-3 19 78 77 70-90 1.92
aPloidy value is the ratio of channel positions (fluorescence) obtained for the G1 peaks from a
FACSII analysis for tumour cells versus normal human lymphocytes.
times ranged from around 20h for OAW42, PXN/94, CHI
and SKOV-3 to around 30h for 41M and HX/62, to a
longest time of 48 h for line 59M. Cytogenetic analysis
revealed a large range in mean chromosome number; some
lines being diploid (PXN/94, PA-1, 41M, OAW28, and
CH1), others being hyper-diploid (59M, OVCAR-3 and
OAW42), while SKOV-3 and HX/62 were close to tetra-
ploid. Of the aneuploid tumour lines, examination for double
minutes indicated their presence only in the SKOV-3 line.
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Cytotoxicity ofplatinum complexes
The cytotoxicities of cisplatin, iproplatin, carboplatin and
tetraplatin against the ten cell lines as determined by tritiated
thymidine or leucine uptake are shown in Figure 2. In
addition, the individual IC50 values, with the range in
observed values from at least two independent experiments,
are shown in Table IV. These data indicate that large
differences in cytotoxicity exist across the lines for each
platinum complex. Some lines (e.g. SKOV-3 and HX/62)
appear to be relatively resistant to all four agents, while
others such as 41M and OAW28 are consistently sensitive. A
comparison of thymidine versus leucine IC50 values for each
agent reveals a good correlation between assays, the leucine
values generally being slightly higher throughout. Table IV
shows the good reproducibility of IC50 values obtained
across independent experiments as indicated by the small
ranges in observed values.
In addition to the labelled uptake assays, cytotoxicity was
determined for some of the lines using the XTT assay (a
modification of the MTT assay) and by soft agar cell
cloning. Results using these assays are shown in Table V,
with the thymidine and leucine values also included for
comparison. For the XTT assay, IC50 values were quite
variable in comparison with the uptake assays. In general,
values from the XTT assay were higher (up to 10-fold). In
particular, determinations using tetraplatin were subject to
the largest differences between the assays. However, for
some lines and some agents (notably cisplatin) there was
much closer agreement between the three assays.
A comparison of IC50 values obtained from the soft agar
cloning assay and the uptake assays is shown in Table V.
Only two lines (PXN/94 and PA-1) gave sufficiently work-
able cloning efficiencies in our hands. In addition it should
be noted that drug exposure was continuous for 14 days in
the cell cloning experiments, not 4 days. Nevertheless, these
data indicate a much closer agreement between assays than
those observed for the XTT assay. In general, IC50 values are
lower with the cloning assay, probably resulting from the
longer exposure time. Results appear to be consistent across
all four agents investigated.
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Figure 2 Cytotoxicity as assessed by tritiated thymidine or
leucine uptake for the 10 ovarian carcinoma cell lines for: a,
cisplatin;.b, iproplatin; c, carboplatin and d, tetraplatin. Leucine
(open boxes), thymidine (hatched boxes).
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Table IV Sensitivity of the 10 human ovarian carcinoma cell lines to 96-h exposure to cisplatin, iproplatin, carboplatin or tetraplatin
Cisplatin
Cell line Leucine Thymidine
Iproplatin
Leucine Thymidine
Carboplatin
Leucine Thymidine
Tetraplatin
Leucine Thymidine
HX/62 8.8
(7-10.7)
PXN/94 1.6
(1.2-2)
OVCAR-3 0.25
(0.25-0.26)
PAl 0.15
(0.11-0.19)
OAW42 0.67
(0.64-0.7)
59M 0.78
(0.57-1.0)
41M 0.19
(0.17-0.21)
OAW28 0.44
(0.38-0.5)
CHI 0.21
(0.28-0.15)
SKOV-3 3.4
(4.2-2.6)
Values are IC50(PM). Mean of two or more independent determinations. Figures in parentheses represent the range in observed IC50 values.
Table V A comparison of IC50 values obtained using leucine and
thymidine uptake and XTT and soft agar colony assays
IC50 (1iM)
Cell Platinum XTT or
line analogue cloning Leucine Thymidine
XTT
HX/62 Cisplatin 3.0 7.0 2.5
OVCAR-3 Cisplatin 0.3 0.25 0.18
Iproplatin 4.5 0.97 0.69
Carboplatin 8.6 4.5 0.54
OAW42 Tetraplatin 3.4 0.45 0.36
59M Cisplatin 1.9 1.0 0.37
Iproplatin 30 8.8 2.6
Carboplatin 35 13.0 2.7
Tetraplatin 7.0 0.84 0.38
41M Cisplatin 0.66 0.17 0.05
CHI Cisplatin 0.52 0.25 0.17
Tetraplatin 1.8 0.47 0.55
SKOV-3 Iproplatin 33 12 14
Soft agar colony assay
PXN/94 Cisplatin 1.1 1.2 0.94
Iproplatin 2.6 10.0 3.9
Carboplatin 4.6 13.0 4.8
Tetraplatin 0.09 0.15 0.14
PAl Cisplatin 0.1 0.11 0.14
Iproplatin 0.8 3.6 1.5
Carboplatin 0.25 2.0 0.6
Tetraplatin 0.24 0.45 0.46
Plating efficiencies: PXN/94, 25%; PAl, 0.15-1.5%.
Discussion
Ten human ovarian carcinoma cell lines have been investi-
gated in terms of biological properties and sensitivity to four
platinum complexes in order to assess their applicability as
an in vitro screen for the discovery of new chemotherapeutic
agents. The biological properties of the lines were consistent
with them being of human ovarian carcinoma origin. In
particular, all lines contained human chromosomes,
expressed antigens specific for human cells, exhibited proper-
ties of epithelial cells and reacted positively against anti-
bodies possessing some specificity towards ovarian
carcinoma (the HMFG2 and OC 125 markers).
Experiments investigating the cytotoxicity of four platinum
complexes revealed many interesting features. The most
obvious finding is the large range in sensitivity observed
across the lines to each agent (Figure2). In addition, by
comparing sensitivities to each agent, it is apparent that
some lines, such as SKOV-3 and HX/62, are consistently the
most resistant whereas others, such as OAW28 and 41M, are
generally the most sensitive. In terms of the thymidine
uptake IC50 values, there is an 86-fold difference in sensiti-
vity for cisplatin between the most resistant line (SKOV-3)
and the most sensitive (41M). For iproplatin, the total
difference in sensitivity is 37-fold (SKOV-3 to OAW42), for
carboplatin it is 54-fold (SKOV-3 to 41M) and for tetra-
platin it is 64-fold (SKOV-3 to PXN/94). With reference to
the ranking of agents, cisplatin was the most cytotoxic in
seven of the lines, iproplatin was most cytotoxic in the
OAW42 line, while tetraplatin was the most cytotoxic in two
of the lines (HX/62 and PXN/94). In terms of sensitivity, it
should be noted that as no drug-free recovery period is
allowed during the assay, some over-estimation of sensitivity
may occur where a reversible effect exists. In general, drug
ranking correlated well with previously obtained preclinical
and clinical data with cisplatin showing greater chemical
reactivity than carboplatin or iproplatin.
To emphasise these differences, for each agent, lines have
been ranked relative to the IC50 value (thymidine uptake) for
the most resistant SKOV-3 cell line. Relative sensitivities
(IC50 SKOV-3/IC50 line x) are shown plotted in histogram
form in Figure 3. In this way, the higher the value the
greater the sensitivity. Figure 3 indicates that, as well as the
large differences in cytotoxicity observed across the lines for
each agent, some individual lines show striking differential
sensitivity. This is most apparent in the PXN/94 line. While
it is quite resistant to cisplatin, iproplatin and carboplatin, it
is extremely sensitive to tetraplatin. Conversely, the
OVCAR-3 line, while being in the mid-range of sensitivity to
cisplatin, iproplatin and carboplatin, in comparison to other
cell lines is somewhat resistant to tetraplatin.
As an additional means of investigating patterns of res-
ponse to the four agents within these 10 lines, a Spearman
rank coefficient analysis has been performed with the six
possible pairings of agent using both the thymidine and
leucine data. Such an analysis is shown in Table VI for
thymidine and leucine uptake. From such an analysis, a high
and statistically significant correlation coefficient for a given
pair of compounds is indicative of a similar pattern of
response in the set of cell lines, whereas a low, non-
significant coefficient, indicates that the two compounds are
acting in different ways. From Table VI, a remarkable
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Figure 3 Relative sensitivity of the cell lines (in terms of sensitivity of the SKOV-3 line), to cisplatin (filled boxes), iproplatin
(hatched boxes), carboplatin (open boxes) and tetraplatin (crossed boxes). Values are from the thymidine uptake assay.
Table VI Spearman rank correlation coefficients (re) for thymidine and leucine IC,0 data
Significance
Combination rS Probability of coefficient
Thymidine
Cisplatin/iproplatin 0.806 P<0.01 Highly significant
Cisplatin/carboplatin 0.939 P<0.01 Highly significant
Iproplatin/carboplatin 0.867 P<0.01 Highly significant
Tetraplatin/cisplatin 0.385 P>0.05 Not significant
Tetraplatin/iproplatin 0.476 P>0.05 Not significant
Tetraplatin/carboplatin 0.494 P>0.05 Not significant
Leucine
Cisplatin/iproplatin 0.733 0.01 <P<0.05 Significant
Cisplatin/carboplatin 0.988 P<0.01 Highly significant
Iproplatin/carboplatin 0.673 P>0.05 Not significant
Tetraplatin/cisplatin 0.224 P>0.05 Not significant
Tetraplatin/iproplatin 0.188 P> 0.05 Not significant
Tetraplatin/carboplatin 0.236 P> 0.05 Not significant
See Snedecor & Cochran (1967) for details of Spearman rank correlation.
feature of the results, particularly with the thymidine uptake
values, is that coefficients are uniformly high for all combi-
nations not involving tetraplatin, and uniformly low for
combinations with tetraplatin. It is clear from such an
analysis that cisplatin, iproplatin and carboplatin appear to
elicit a similar pattern of response in this set of cell lines.
Conversely, tetraplatin appears to elicit a completely differ-
ent pattern of response.
It is apparent that this panel of human ovarian tumour
lines is capable of displaying both cell-determined and
structure-determined differences in cytotoxicity to th-e four
calibrating platinum species. As such it may provide a useful
adjunct to other tumour models in the structure-activity
ranking of potential new platinum-containing drugs. The
mechanisms underlying the observed differences in cyto-
toxicity are unclear at present. Of the biological properties
investigated (Table III), no obvious correlations with popula-
tion doubling time are apparent. With reference to cyto-
genetic determinations, it is of interest that the two most
resistant cell lines (SKOV-3 and HX/62) are tetraploid,
whereas the more sensitive lines (OAW28 and 41M) have a
diploid complement of chromosomes. However, the OAW42
line, which is also near tetraploid, exhibits intermediate
sensitivity to cisplatin, carboplatin and tetraplatin, and is
extremely sensitive to iproplatin. Of many biochemical
factors which may mediate platinum cytotoxicity, it is pos-
sible that differences in platinum uptake, DNA platination,
intrinsic glutathione and/or metallothionein levels, the
presence of genes conferring multidrug resistance or DNA
repair of platinum-induced lesions are of importance (for
reviews see McBrien & Slater, 1986; Nicolini, 1988). The
possible involvement of these factors remains to be deter-
mined.
Further to the uptake assays, cytotoxicity was compared
using a modification of the MTT assay and by a soft agar
clonogenic assay. The MTT assay has been proposed as a
practicable alternative to the more conventional uptake or
clonogenic assays for routine drug screening (Mossman,
1983; Ruben & Neubauer, 1987; Hill, 1987). Indeed the NCI
drug screening programme has recently adopted this assay
(Alley et al., 1988) in preference to the more time consuming
human tumour stem cell assay previously used (Salmon et
al., 1978; Shoemaker et al., 1985). In our hands the XTT
assay produced IC50 values which were generally higher and
more variable than the two uptake assays (Table V). In
particular, values involving tetraplatin were subject to the
greatest variability. In contrast, data where the soft agar
clonogenic assay of Salmon et al. (1978) was used (Table V)
indicate a much closer agreement in IC50 value with the
uptake assays. Notably, the high sensitivity of the PXN/94
line to tetraplatin is also apparent from the soft agar assay.
In consideration of practicability, the variables inherent in
the MTT assay as previously alluded to (Twentyman &
Luscombe, 1987; Hill, 1987) and the high IC50 values we
OAW 59M
42
41M OAW
28
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have observed (particularly with tetraplatin) lead us to
conclude that, for these lines, an assay endpoint involving
thymidine uptake may be the most appropriate in a routine
screening context.
In conclusion, these cell lines may provide a useful
component of a screening assay aimed at the discovery and
development of novel platinum-containing chemotherapeutic
agents. We propose to use the thymidine uptake assay and
six lines for routine screening. The six lines chosen are
SKOV-3 and HX/62, on the basis of their intrinsic resistance
to the calibrating agents, 41M on the basis of sensitivity,
PXN/94 and OVCAR-3 as they show evidence of differential
sensitivity, and CH-1 as a representative of a number of lines
of intermediate sensitivity. In addition, from Table I, it is
apparent that these six lines are representative of tumours
from both untreated and treated (chemotherapy and radio-
therapy) patients, from solid xenograft tumours and ascites
and (from Table II) are usable at a range of in vitro passage
number. In addition, five of these six lines (41M being the
exception) have xenograft counterparts in the nude mouse,
thus providing a directly comparable pharmacological model
for the further assessment of interesting new agents.
This work was supported by grants to The Institute of Cancer
Research: Royal Cancer Hospital from the Cancer Research
Campaign and the Medical Research Council, The Johnson Matthey
Technology Centre and Bristol-Myers Oncology (UK). Our grateful
thanks are due to Dr E. Wiltshaw (Royal Marsden Hospital) for the
provision of ovarian carcinoma ascites samples, to Dr L.I. Hart
(ICR) for performing the statistical analyses, to Dr M. Pera (ICR)
for assistance with intermediate filament and marker analysis, to Dr
M. Ormerod (ICR) for performing the cell ploidy determinations, to
Dr R. McClelland (St Georges Hospital, London SW17) for per-
forming the oestrogen receptor analysis, to Dr M. Wolpert-
DeFilippes (NCI) for the supply of tetraplatin and to Dr K. Paull
(NCI) for the gift of XTT. Thanks are also due to Miss A.
Robinson for efficient typing of the manuscript.
References
ALLEY, M.C., SCUDIERO, D.A., MONKS, A. & 7 others (1988).
Feasibility of drug screening with panels of human tumour cell
lines using a microculture tetrazolium assay. Cancer Res., 48,
589.
ANDERSON, W.K., QUAGLIATO, D.A., HAUGWITZ, R.D.,
NARAYANAN, V.L. & WOLPERT-DEFILIPPES, M.K. (1986). Syn-
thesis, physical properties, and antitumour activity of tetraplatin
and related tetrachloroplatinum(IV) stereoisomers of 1,2-
diaminocyclohexane. Cancer Treat. Rep., 70, 997.
BAST, R.C., FEENEY, M., LAZARUS, H., NADLER, I.M., COLVIN, R.B.
& KNAPP, R.C. (1981). Reactivity of a monoclonal antibody with
human ovarian carcinoma. J. Clin. Invest., 68, 1331.
BAST, R.C., KLUG, J.L. & JOHN, E. (1983). A radioimmunoassay
using a monoclonal antibody to monitor the cause of epithelial
ovarian cancer. N. Engl. J. Med., 309, 383.
BOYD, M.R. (1986). National Cancer Institute new drug development
program. In Accomplishments in Oncology, Vol. 1, Frei, E.J. &
Freireich, E.J. (eds) p. 68. Lippincott: Philadelphia.
BUAMAH, P.K., CORNELL, C., SKILLEN, A.W., CANTWELL, B.M.J. &
HARRIS, A.L. (1987). Initial assessment of tumour-associated
antigen CA-125 in patients with ovarian, cervical and testicular
tumours. Clin. Chem., 33, 1124.
BUICK, P.N., PULLANO, R. & TRENT, J.M. (1985). Comparative
properties of five human ovarian adenocarcinoma cell lines.
Cancer Res., 45, 3668.
BURCHENAL, J.H., KALAKER, K., DEW, K. & LOKYST, L. (1979).
Rationale for development of platinum analogs. Cancer Treat.
Rep., 63, 1493.
BURCHENAL, J.H., IRANI, G., KERN, K., LOKYS, L. & TURKEVICH,
J. (1980). 1,2-Diaminocyclohexane platinum derivatives of poten-
tial clinical value. Rec. Res. Cancer Res., 74, 146.
CALVERT, A.H., HARLAND, S.J., NEWELL, D.R., SIDDIK, Z.H. &
HARRAP, K.R. (1985). Phase I studies with carboplatin at the
Royal Marsden Hospital. Cancer Treat. Rev., 12 (suppl. A), 51.
FOGH, J., FOGH, J.M. & ORFEO, T. (1977). One hundred and twenty-
seven cultured tumour cell lines producing tumours in nude mice.
J. Natl Cancer Inst., 59, 221.
FREI, E. (1982). The national chemotherapy program. Science, 217,
600.
HAMILTON, T.C., YOUNG, R.C., McKOY, W.M. & 7 others (1983).
Characterisation of a human ovarian carcinoma cell line (NIH:
OVCAR-3) with androgen and oestrogen receptors. Cancer Res.,
43, 5379.
HARRAP, K.R. (1985). Preclinical studies identifying carboplatin as a
viable cisplatin alternative. Cancer Treat. Rev., 12 (suppl. A), 21.
HARRAP, K.R., JONES, M., WILKINSON, C.R. & 5 others (1980).
Antitumour, toxic and biochemical properties of cisplatin and
eight other platinum complexes. In Cisplatin. Current Status and
New Developments, Prestayko, A.W., Crooke, S.T. & Carter,
S.K. (eds) p. 193. Academic Press: New York.
HILL, B.T. (1987). In vitro screening of new drugs and analogues -
specificity and selectivity. Cancer Treat. Rev., 14, 197.
KELLAND, L.R., BURGESS, L. & STEEL, G.G. (1987). Characterisa-
tion of four new cell lines derived from human squamous
carcinomas of the uterine cervix. Cancer Res., 47, 4947.
MAKIN, C.A., BOBROW, L.G. & BODMER, W.F. (1984). Monoclonal
antibody to cytokeratin for use in routine histopathology. J.
Clin. Pathol., 37, 975.
McBRIEN, D.C.H. & SLATER, T.F. (eds) (1986). Biochemical Mechan-
isms of Platinum Antitumour Drugs. IRL Press: Oxford.
MOSSMAN, T. (1983). Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity assays.
J. Immunol. Methods, 65, 55.
NICOLINI, M. (ed) (1988). Platinum and Other Metal Coordination
Compounds in Cancer Chemotherapy. Martinus Nijhoff: Boston.
PECKHAM, M.J., HORWICH, A., BRADA, M., DRURY, A. &
HENDRY, W.F. (1985). Cis-diammine-1,1-cyclobutane di-
carboxylate platinum II (carboplatin) in the treatment of testicu-
lar germ cell tumours: a preliminary report. Cancer Treat. Rev.,
12 (suppl. A), 101.
PERA, M.F., BLASCO-LAFITA, M.J., COOPER, S., MASON, M., MILLS,
J. & MONAGHAN, P. (1988). Analysis of cell differentiation
lineage in human teratomas using new monoclonal antibodies to
cytostructural antigens of embryonal carcinoma cells. Differentia-
tion (in the press).
RUBEN, R.L. & NEUBAUER, R.H. (1987). Semiautomated colori-
metric assay for in vitro screening of anticancer compounds.
Cancer Treat. Rep., 71, 1141.
SALMON, S.E., HAMBURGER, A.W., SOEHNLEN, B., DURIE, B.E.M.,
ALBERTS, D.S. & MOON, T.E. (1978). Quantification of differen-
tial sensitivity of human tumour stem cells to anticancer drugs.
N. Engl. J. Med., 298, 1321.
SCUDIERO, D., SHOEMAKER, R., PAULL, K. & 4 others (1987). A
new tetrazolium reagent for a simplified growth and drug
sensitivity assay of human tumour cell lines. Proc. Am. Assoc.
Cancer Res., 28, 421.
SHOEMAKER, R.H., WOLPERT-DEFILIPPES, M.K., KERN, D.H. & 8
others (1985). Application of a human tumour colony-forming
assay to new drug screening. Cancer Res., 45, 2145.
SIMON, W.E., ALBRECHT, M., HANSEL, M., DIETEL, M. & HOLZEL,
F. (1983). Cell lines derived from human ovarian carcinomas:
growth stimulation by gonadotropic and steroid hormones. J.
Natl Cancer Inst., 70, 839.
SNEDECOR, G.W. & COCHRAN, W.G. (1967). Statistical Methods, 6th
edn, p. 193. Iowa State University Press: Ames, Iowa.
STALL,. K.E. & MARTIN, E.W. (1981). Plasma carcinoembryonic
antigen levels in ovarian cancer patients: a chart review and
survey of published data. J. Reprod. Med., 26, 75.
TAYLOR-PAPADIMITRIOU, J., PETERSON, J.A., ARKLIE, J.,
BURCHELL, J., CERIANI, R.L. & BODMER, W.F. (1981). Mono-
clonal antibodies to epithelium-specific components of the
human milk fat globule membrane: production and reaction with
cells in culture. Int. J. Cancer, 28, 17.
TWENTYMAN, P.R. & LUSCOMBE, M. (1987). A study of some
variables in a tetrazolium dye (MTT) based assay for cell growth
and chemosensitivity. Br. J. Cancer, 56, 279.
VAN HAAFTEN-DAY, C., RUSSELL, P., RUGG, C., WILLS, E.J. &
TATTERSALL, M.H.N. (1983). Flow cytometric and morpho-
logical studies of ovarian carcinoma cell lines and xenografts.
Cancer Res., 43, 3725.534 C.A. HILLS et al.
VENDITTI, J.M. (1983). The National Cancer Institute antitumour
drug discovery program, current and future perspectives: a
commentary. Cancer Treat. Rep., 67, 767.
WARD, B.G. & CRUICKSHANK, D.J. (1987). Circulating tumour
associated antigen detected by the monoclonal antibody HMFG2
in human epithelial ovarian cancer. Int. J. Cancer, 39, 30.
WARD, B.G., LOWE, D.G. & SHEPHERD, J.H. (1987). Patterns of
expression of a tumor associated antigen, defined by the mono-
clonal antibody HMFG2, in human epithelial ovarian carcinoma.
Cancer, 60, 787.
WILSON, A.P. (1984). Characterisation of a cell line derived from the
ascites of a patient with papillary serous cystadenocarcinoma of
the ovary. J. Natl Cancer Inst., 72, 513.
WILTSHAW, E. (1985). Ovarian trials at the Royal Marsden. Cancer
Treat. Rev., 12 (suppl. A), 67.
WILTSHAW, E. & CARR, B. (1974). In Recent Results in Cancer
Research, Connors, T.A. & Roberts, J.J. (eds) p. 178. Springer-
Verlag: Berlin.
WOLF, C.R., HAYWARD, I.P., LAWRIE, S.S. & 6 others (1987).
Cellular heterogeneity and drug resistance in two ovarian adeno-
carcinoma cell lines derived from a single patient. Int. J. Cancer,
39, 695.
WOODS, L.K., MORGAN, R.T., QUINN, L.A., MOORE, G.E., SEMPLE,
T.H. & STEDMAN, K.E. (1979). Comparison of four new cell lines
from patients with adenocarcinoma of the ovary. Cancer Res.,
39, 4449.
ZEUTHEN, J. NORGAARD, J.O.R., AVNER, P. & 6 others (1980).
Characterisation of a human ovarian teratocarcinoma-derived
cell line. Int. J. Cancer, 25, 19.